[go: up one dir, main page]

MX2007003624A - Peptidos y derivados tipo peptido ligando alterado de la hsp60 y composiciones farmaceuticas. - Google Patents

Peptidos y derivados tipo peptido ligando alterado de la hsp60 y composiciones farmaceuticas.

Info

Publication number
MX2007003624A
MX2007003624A MX2007003624A MX2007003624A MX2007003624A MX 2007003624 A MX2007003624 A MX 2007003624A MX 2007003624 A MX2007003624 A MX 2007003624A MX 2007003624 A MX2007003624 A MX 2007003624A MX 2007003624 A MX2007003624 A MX 2007003624A
Authority
MX
Mexico
Prior art keywords
peptides
pharmaceutical compositions
hsp60
apl
mechanisms
Prior art date
Application number
MX2007003624A
Other languages
English (en)
Inventor
Horta Maria Del Carmen Dominguez
Palomares Gabriel Ramon Padron
Marin Nelia Lopez
Perez Norailys Lorenzo
Betancourt Ariana Barbera
Garcia Ariadna Hernandez
Cordova Vivian Morera
Diaz Carelia Cosme
Garcia Nelson J Merino
Bonachea Ariel Vazquez
Alba Jose Suarez
Original Assignee
Ct Ingenieria Genetica Biotech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Ingenieria Genetica Biotech filed Critical Ct Ingenieria Genetica Biotech
Publication of MX2007003624A publication Critical patent/MX2007003624A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Peptidos de la proteina humana de estres termico de 60 kDa que constituyen epitopes para celulas T, asi como peptidos derivados de ellos, los cuales estan modificados en los sitios de contacto con la molecula MHC,utiles para inducir mecanismos de tolerancia periferica, en particular mecanismos inductores de anergia o mediados por clones de celulas T regulatorias en pacientes con Artritis Reumatoide; la invencion tambien refiere composiciones farmaceuticas que comprenden tales peptidos para tratamiento de la Artritis Reumatoide.
MX2007003624A 2004-09-24 2005-09-22 Peptidos y derivados tipo peptido ligando alterado de la hsp60 y composiciones farmaceuticas. MX2007003624A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CU20040207A CU23504A1 (es) 2004-09-24 2004-09-24 Péptidos y derivados tipo apl de la hsp60 y composiciones farmacéuticas
PCT/CU2005/000008 WO2006032216A2 (es) 2004-09-24 2005-09-22 Peptidos y derivados tipo apl de la hsp60 y composiciones farmacéuticas

Publications (1)

Publication Number Publication Date
MX2007003624A true MX2007003624A (es) 2007-06-13

Family

ID=40273413

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007003624A MX2007003624A (es) 2004-09-24 2005-09-22 Peptidos y derivados tipo peptido ligando alterado de la hsp60 y composiciones farmaceuticas.

Country Status (17)

Country Link
US (2) US8383771B2 (es)
EP (2) EP1803732B1 (es)
JP (1) JP4755649B2 (es)
KR (2) KR101035283B1 (es)
CN (2) CN101935345B (es)
AR (2) AR051928A1 (es)
AT (1) ATE546462T1 (es)
AU (2) AU2005287757B2 (es)
BR (2) BR122018077204B8 (es)
CA (2) CA2797769C (es)
CU (1) CU23504A1 (es)
DK (2) DK2371847T3 (es)
ES (2) ES2445707T3 (es)
MX (1) MX2007003624A (es)
RU (1) RU2361877C2 (es)
WO (1) WO2006032216A2 (es)
ZA (1) ZA200702938B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107011431B (zh) 2007-01-30 2020-11-06 埃皮瓦克斯公司 调节性t细胞表位、组合物及其用途
CU23701A1 (es) * 2008-12-29 2011-09-21 Ct Ingenieria Genetica Biotech Método de tratamiento de enfermedades inflamatorias intestinales y diabetes tipo i
US8680241B2 (en) * 2009-09-06 2014-03-25 Protab Ltd. Humanized antibodies specific for HSP65-derived peptide-6 methods and uses thereof
US20110195905A1 (en) * 2009-10-28 2011-08-11 Argentis Pharmaceuticals, Llc Apls for treating arthritis
CU24508B1 (es) * 2017-12-29 2021-04-07 Centro De Ingenieria Genetica Y Biotecnologia Biocubafarma Composición farmacéutica que comprende péptido tipo apl
CU20200026A7 (es) * 2020-04-13 2021-11-04 Ct Ingenieria Genetica Biotecnologia Péptido para el tratamiento del síndrome de la tormenta de citocinas
CN111870697B (zh) * 2020-09-18 2022-09-09 山东鲁抗医药股份有限公司 糖类物质在提高apl型衍生肽稳定性中的应用和冻干组合物
KR102333645B1 (ko) 2021-07-27 2021-12-02 (주)문화전기 각도조절이 용이한 엘이디조명시스템
CN117883547A (zh) * 2021-07-30 2024-04-16 河北菲尼斯生物技术有限公司 Se-dr亲和肽在制备治疗风湿疾病的药物中的用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL8701163A (nl) 1986-09-09 1988-04-05 Nederlanden Staat Gebruik van een peptide voor de bereiding van preparaten voor het verlichten, het behandelen en de diagnose van autoimmuunziekten, in het bijzonder arthritische toestanden, verbindingen die met dit peptide verwant zijn, alsmede farmaceutische en diagnostische preparaten en testkits.
NL8703107A (nl) 1987-12-22 1989-07-17 Nederlanden Staat Polypeptiden en derivaten daarvan, alsmede de toepassing daarvan in farmaceutische en diagnostische preparaten.
US5773570A (en) 1994-05-20 1998-06-30 The Regents Of The University Of California Vaccine compositions and methods useful in inducing immune protection against arthritogenic peptides involved in the pathogenesis of rheumatoid arthritis
GB9419553D0 (en) 1994-09-27 1994-11-16 Univ Bristol Polypeptides and their use in the treatment of auto-immune disease
US6180103B1 (en) 1994-12-21 2001-01-30 Yeda Research And Development Co., Ltd. Peptide p277 analogs, and pharmaceutical compositions comprising them for treatment or diagnosis of diabetes
GB9519737D0 (en) * 1995-09-27 1995-11-29 Peptide Therapeutics Ltd Polypeptides and their use in treatment and prophylaxis of auto-immune
TW575583B (en) * 1996-04-24 2004-02-11 Akzo Nobel Nv Novel peptides suitable for use in antigen specific immunosuppressive therapy
US5993803A (en) 1996-08-30 1999-11-30 Yeda Research And Development Co., Ltd. Method of reducing the severity of host vs graft reaction by down-regulating hsp60 autoimmunity
GB9911772D0 (en) 1999-05-21 1999-07-21 Semmelweis University Of Medic Diagnosis and treatment of atherosclerosis
US20020169302A1 (en) * 1999-08-23 2002-11-14 Genesis Research And Development Corp. Ltd. Compositions isolated from bovine mammary gland and methods for their use
AU784623B2 (en) * 1999-12-15 2006-05-18 Develogen Israel Ltd. Fragments and antagonists of heat shock protein 60
AU2002247004A1 (en) 2001-01-19 2002-07-30 Cambridge Scientific, Inc. Methods of diagnosis and treatment of osteoporosis

Also Published As

Publication number Publication date
US8324164B2 (en) 2012-12-04
US20090171069A1 (en) 2009-07-02
ES2386498T3 (es) 2012-08-22
CA2797769C (en) 2015-09-15
BRPI0515893B1 (pt) 2020-09-15
CA2581110C (en) 2013-04-02
KR20100028645A (ko) 2010-03-12
DK1803732T3 (da) 2012-05-29
EP1803732A2 (en) 2007-07-04
CA2797769A1 (en) 2006-03-30
KR20070073787A (ko) 2007-07-10
AR051928A1 (es) 2007-02-21
CN101935345B (zh) 2013-12-11
JP4755649B2 (ja) 2011-08-24
BRPI0515893A8 (pt) 2019-01-02
CN101935345A (zh) 2011-01-05
CN101065398A (zh) 2007-10-31
CN101065398B (zh) 2012-12-19
AU2005287757B2 (en) 2010-07-29
RU2007115411A (ru) 2008-10-27
US20100144642A1 (en) 2010-06-10
BR122018077204B8 (pt) 2021-07-27
AR074924A2 (es) 2011-02-23
CA2581110A1 (en) 2006-03-30
RU2361877C2 (ru) 2009-07-20
US8383771B2 (en) 2013-02-26
EP2371847A1 (en) 2011-10-05
BRPI0515893A (pt) 2008-08-12
BRPI0515893B8 (pt) 2021-05-25
ZA200702938B (en) 2008-08-27
ATE546462T1 (de) 2012-03-15
WO2006032216A3 (es) 2007-05-18
CU23504A1 (es) 2010-04-13
KR101054332B1 (ko) 2011-08-04
EP1803732B1 (en) 2012-02-22
AU2010219312A1 (en) 2010-09-23
AU2010219312B2 (en) 2011-10-06
EP2371847B1 (en) 2013-11-20
AU2005287757A1 (en) 2006-03-30
JP2008514553A (ja) 2008-05-08
WO2006032216A2 (es) 2006-03-30
DK2371847T3 (da) 2014-02-03
KR101035283B1 (ko) 2011-05-18
BR122018077204B1 (pt) 2020-01-28
ES2445707T3 (es) 2014-03-04

Similar Documents

Publication Publication Date Title
MX2010003574A (es) Anticuerpos il-23.
MX351247B (es) Composiciones inmunogenicas que comprenden polipeptidos de mycobacterium tuberculosis y fusiones de los mismos.
EA201892619A1 (ru) Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
WO2004078098A3 (en) Peptides associated with hla-dr mhc class ii molecules involved in autoimmune diseases
MX2022015847A (es) Proteinas de union a cd123 y composiciones y metodos relacionados.
MY177970A (en) Bcma (cd269/tnfrsf17) -binding proteins
WO2006082406A3 (en) Human antibodies and proteins
ATE372784T1 (de) Rekombinante proteine, die epitope des humanen papillomavirus inseriert in einem adenylatecyclase protein oder in dessen fragmenten tragen, und deren terapeutischen verwendung.
CY1117115T1 (el) Καινοτομος ανοσοθεραπεια εναντι ογκων και νευρωνων του εγκεφαλου
CY1115999T1 (el) Νεα και ισχυρα mhc- κατηγοριας ιι πεπτιδια που προερχονται απο σουρβιβινη και νευροκανη
WO2010034032A3 (en) Methods for preparing purified polypeptide compositions
WO2005049073A3 (en) Proteins belonging to the bcl-2 family and fragments thereof, and their use in cancer patients
EP3211001A3 (en) Superagonists and antagonists of interleukin-2
EA201000208A1 (ru) Композиция опухолеассоциированных пептидов и относящаяся к ним противораковая вакцина
DK1572087T3 (da) Antistoffer med cancerantigen TMEFF2 og anvendelser deraf
MX2010006388A (es) Bis-piridilpiridonas como antagonistas del receptor 1 de la hormona concentradora de melanina.
MX2007003624A (es) Peptidos y derivados tipo peptido ligando alterado de la hsp60 y composiciones farmaceuticas.
WO2011053789A3 (en) Pharmaceutical composition and methods to enhance cytotoxic t-cell recognition and maintain t-cell memory against a pathogenic disease
WO2007034489A3 (en) Immunogenic fragments of t-cell receptor constant domains and peptides derived therefrom
NZ524329A (en) IgE receptor antagonists that compete with IgE134 for binding to the receptor
WO2006125201A3 (en) Anti-biotin-pegylated-mcp-1 mutein antibodies, compositions, methods and uses
JOP20190101A1 (ar) أنظمة علاج
WO2004031354A3 (en) Human sarcoma-associated antigens
SG162829A1 (en) Humanised antibodies specific for nogo-a and pharmaceutical uses thereof
MX2009011851A (es) Plasmidos de dna que tienen expresion y estabilidad mejoradas.

Legal Events

Date Code Title Description
FG Grant or registration